The EAACI White Paper tackles the research-innovation-quality of care nexus for allergic diseases and asthma. It:

• Provides a critical view of allergic diseases and the asthma landscape in Europe
• Presents an informed analysis of future trends
• Identifies and promotes research priorities in allergy, asthma and clinical immunology
• Sets standards and quality criteria
• Provides guidance and training for practice and research

The White Paper is a collaborative effort of the whole EAACI family, including Sections, Interest Groups and Working Groups, as well as patients’ organisations.

Connecting science with the transformation of care

There is a single light of science, and to brighten it anywhere is to brighten it everywhere.
Isaac Asimov

Bridging past, present and future under the EAACI umbrella confirms the Academy’s dedication both to science and humanity. Our Academy traces its roots back more than six decades. The Academy founders were clinicians and scientists who believed in a simple but powerful principle: by sharing observations, discoveries and ideas they would be more likely to find cures for the allergic diseases than if they worked alone. This philosophy remains the core value of EAACI: more than 10,000 members share the aims of spreading knowledge and developing the next generation of researchers, clinicians and educators who will improve standards of care and make the world a healthier place. Its committed membership is the true identity of EAACI.

EAACI has grown spectacularly in the last few years, in numbers of members actively involved, in the quality of its meetings and educational programmes, and in public recognition. We measure our success by organising the best allergy meetings, by developing and delivering accurate and up-to-date educational products and events for allergy practice, by efficiently opening up to our members, to other specialists and to the general public and for society’s needs. How do we manage to achieve all these high standards? We owe this to the EAACI core values: teamwork, innovation, an increased level of competence, friendship, democracy and dedication.

The core strength of all EAACI events is the Academy’s Annual Congress. Whether as an opportunity to share new scientific discoveries, to network with old friends and identify new research partners, or keep up to date on industry developments, the EAACI Congress is truly connecting science with the transformation of care. The Scientific Programme Committee has prepared an excellent programme ranging from top-notch plenary sessions to interactive symposia and postgraduate courses, and to novel patent abstract sessions. Be enthusiastic participants in the EAACI Allergy Knowledge Test, showcase your best science, ask questions and interact with your colleagues in the abstract sessions, meet the HQ staff and the exhibitors in the interactive exhibition hall, join the EAACI National Societies Forum and village and discuss how to further improve the bidirectional translation of allergy science and education from a national to pan-European level. The main ingredient for the “recipe of success” for this meeting is the EAACI membership itself, with all its brilliant and enthusiastic proposals, initiatives and active participation both in shaping the meeting programme and attending the meeting itself.

Technology has changed how people interact and learn. Nowhere is this more true than at meetings, where simply listening to a lecturer is being replaced by one-on-one, interactive and virtual education. To help ensure the EAACI Congress retains its place as the must-attend allergy event of the year, EAACI is committing significant resources to enhance the attendee experience. EAACI TV, e-posters, interactive sessions, the EAACI App and other novel tools await you this year in Munich.

I look forward to welcoming participants and friends from around the world to the EAACI Annual Congress where we will continue our mission to drive standards for best science and patient care.

Ioana Agache
EAACI President
Dear EAACI members and friends,

The EAACI Congress in Munich will surely generate an environment full of motivation and knowledge, delivering its theme of “Innovative Solutions for Allergy”. Both the Local and Scientific Organising Committees have made a tremendous effort to prepare this year’s events: allergy needs considerable work in prevention, monitoring, treatment and management. Innovation is imperative so as to achieve better outcomes for patients, physicians and all allergy-related stakeholders.

The EAACI Congress 2018 programme comprises 7 Plenary Symposia, 50 symposia, 11 Sister Society Symposia, 10 interactive workshops and also interactive symposia, along with 12 Learning Lounges and 6 Year in Review Sessions where researchers, clinicians, residents and allied health professionals will discuss, learn and interact. The host city in 2018 is, of course, Munich, with its great mix of cultures and top-ranked universities.

Attendees will have the chance to benefit from the most technologically supported EAACI Congress ever, with EAACI TV, the EAACI App, digital e-Posters and the EAACI Virtual Congress Hubs. EAACI TV, a very interesting broadcasting project which will be launched during the Munich Congress, is aimed at providing free extensive coverage including: highlights of each day’s activities, hot topics, live streaming of key programme activities, interviews with experts, participants and faculty, plenary session insights, and comments from Congress delegates. EAACI TV will give a snapshot of the world’s largest allergy meeting. Meanwhile, the EAACI App will provide delegates with updated information about the Congress, giving access to Congress abstracts and e-posters, allowing delegates to make their own personal calendar, vote in sessions which have polls, and give feedback on speakers and sessions. The e-poster sessions offer a modern sustainable approach to conferences, with all poster sessions being shown on new high-resolution digital e-Poster stands as well as, at the three EAACI Virtual Congress Hubs, saving up to 1800 posters from being printed.

The EAACI Knowledge exam, being held during the EAACI Congress, will this year have two different streams: the general version and a pediatric version. EAACI encourages participation in the exam to help promote our knowledge worldwide.

An interesting new topic at Congress this year is the hosting of a session on allergy innovations that are either patented or in the process of being patented. The session will be an opportunity to brainstorm, network and to learn about the allergy solutions of tomorrow!

Also in Munich, there will be an EAACI–DGAKI Joint Session about innovative therapeutic approaches with novel antibodies and small molecules in allergic diseases. This session is intended to discuss all the new possibilities of diagnostic and treatment management in allergy and will be held on the Saturday of Congress.

Meanwhile, the Clinical Village once again boasts interactive stations where attendees may benefit from the knowledge of experienced specialists in many different fields.

The EAACI Allied Health Day will include busy sessions about food allergy, eosinophilic esophagitis, FPIES and immunotherapy to food. There will also be a very interesting talk about EAACI Allergy Competencies for Allied Health Professionals.

The EAACI National Allergy Society (NAS) Dual Membership is now available to all new EAACI members of 14 different national allergy societies, entitling them to annual EAACI membership for a fee 30 EUR. If you are not yet an EAACI member I take this opportunity to encourage you to apply, indicating which National Allergy Society you are a member of and filling in your valid national society membership number. From 2019 this offer will be opened to existing EAACI members of 14 different national allergy societies, entitling them to annual EAACI membership.

After the EAACI Congress, two further large EAACI events are to come this year: the Food Allergy and Anaphylaxis Meeting in Copenhagen (18–20 October) and the International Severe Asthma Forum in Madrid (8–10 November). I encourage you to check their interesting programmes on the EAACI website.

2018 looks set to be a year for which we can all be proud, full of scientific activity in which innovation, dedicated to allergy science, is committed to improving our patients’ health.

I wish you all the best.

Dario Antolin Amérgio
EAACI Newsletter Editor
SUMMARY

President’s Desk
3 Connecting science with the transformation of care

Letter from the Editor
4 Welcome to the newsletter

Opinion Leaders Corner
6 Jolanta Walusiak-Skorupa – Occupational Allergy: towards a healthier working environment

Meet the Person Behind
7 Tomás Chivato – Science Committee Chair
7 Edward Knol – Scientific Media Editor

In the spotlight: Munich
8 EAACI 2018 Congress: Chair’s report
9 Lots of good reasons to attend the NAS Forum!
9 Visit the Clinical Village during the EAACI Congress 2018
10 JM Activities
10 Presidential Symposium
12 Scientific Social Media at #EAACI2018

News
13 EAACI HQ Corner
14 German Society for Allergology and Clinical Immunology
14 Website Editor News
15 PAI: in search of scientific excellence
15 CTA: onwards and upwards
16 Congratulations to the 2018 EAACI Fellowship winners
17 EAACI Task Force on Public Outreach Activities on Immunological Mechanisms in Allergies and Asthma
17 EAACI Guidelines on the use of Biologics in Allergic Diseases and Asthma

Agenda
18 2018 #EAACI Allergy Schools in Tweets
19 EAACI e-PAD Master Class Highlights
20 EAACI Allergy School on Aerobiology and Pollution
21 EAACI Master Class on Biologicals

Science in Brief
22 Mast Cell Disorders: Report from Helsinki 2017 – Michael Rudenko
Occupational Allergy: towards a healthier working environment

Occupational allergy has been recognised since Bernardino Ramazzini first observed work-related respiratory symptoms in the 18th Century, and it still remains the focus of much research. It is one of the most frequent forms of occupational disease, with occupational asthma creating about 15–20% of the overall adult-asthma public burden, mainly due to hypersensitivity to high-molecular-weight allergens (such as flour and enzymes) or to low-molecular-weight agents (such as di-isocyanates), and has a significant socio-economic impact.

Industrial and technological transformations often result in the launch of new emerging respiratory hazards: there are now more than 400 known occupational allergens and the list grows continuously. Despite an observed decline in the incidence of occupational asthma, the question of whether this trend is under control or results from workers’ fear of a lowering of their quality of life after occupational disease is recognised, remains.

To a great extent, occupational allergy may be avoidable through preventive interventions in the workplace, and so an evaluation of different solutions and the development of evidence-based recommendations seems to be crucial. As the dose–response relationship has been documented for many occupational allergens, setting occupational exposure limits should be the most obvious approach. However, controlling allergen concentrations in the workplace may be difficult to achieve, especially in small enterprises e.g. bakeries or farms. Moreover, sensitive subjects can still develop hypersensitivity, which raises the question of individual susceptibility and risk factors for occupational allergy. For instance, identification of atopic individuals, and those with pre-existing nonspecific bronchial hyperresponsiveness, has been proposed for occupational asthma prevention. Even though evidence-based figures are lacking, it seems that pre-employment examination is widely applied in most countries of the world. In such situations when exposure cannot be eliminated below a critical threshold, health surveillance for early signs of disease may be appropriate.

For those who are already sensitised to workplace agents and would like to return to work, the question arises as to whether reduction of exposure may be an alternative to cessation of it. However, it has been shown that a reduction of exposure is associated with a lower likelihood of improvement and recovery of asthma symptoms, as well as a higher risk of worsening of the symptoms and non-specific bronchial hyperreactivity, as compared with complete avoidance of exposure.

The diagnosis of occupational allergy often remains a challenge because there is no simple test for a sufficient level of diagnostic accuracy. Complications arise from the lack of standardised diagnostic methods and occupational allergen extracts for most agents, which is the result of low frequency – sometimes only case reports – of documented sensitisation to particular workplace allergens. In most cases – except for natural rubber latex and cereal flour – the assessment of sIgE reactivity to allergen components has been poorly investigated. The reference method for diagnosing occupational asthma remains the specific inhalation challenge (SIC) with occupational agents. The European Respiratory Society Task Force recently performed harmonised occupational SIC testing in Europe and provided consensus statements on essentials for the practise and interpretation of the test.

There are many aspects in the field of occupational allergy, such as gender-specific differences, that require further research and may have different impacts in work-related allergy or on the emergence of new biomarkers for asthma and allergy that would allow the development of new tools, leading to precision or personalised medicine.

Jolanta Walusiak-Skorupa
Nofer Institute of Occupational Medicine, Department of Occupational Diseases and Environmental Health, Lodz, Poland

**EAACI CALENDAR – IMPORTANT DATES AT A GLANCE**

**May 2018**
- 26 May – EAACI Executive Committee Meeting, EAACI Congress, Munich, Germany
- 26 May – 30 May – EAACI Congress 2018, Munich, Germany
- 28 May – EAACI General Assembly, EAACI Congress, Munich, Germany

**September 2018**
- EAACI Newsletter

**October 2018**
- 1 October – EAACI Fellowships Application for Junior Membership Fellowships 2019 open
- 18 – 20 October – FAAM, Food Allergy and Anaphylaxis Meeting, Copenhagen, Denmark

**November 2018**
- 8 – 10 November – ISAF – International Severe Asthma Forum Madrid, Spain

**December 2018**
- EAACI Newsletter

This calendar shows EAACI’s most important events planned for the coming months. Only events with confirmed dates are listed here. For a complete list of all events, please view the ‘Meetings’ and ‘Education’ pages on www.eaaci.org.
Meet the person behind

**Tomás Chivato, Science Committee Chair**

Tell us about yourself
I am an allergy specialist with more than 30 years’ experience, mainly dedicated to clinical work but also committed to teaching, research, and management. A university professor for more than 25 years, I was responsible for the allergology classes of medical students in the Schools of Medicine of the Complutense University of Madrid (1992–2002) and at the University San Pablo CEU Madrid (2005–2017).

What is your experience with EAACI?
I believe that EAACI is undoubtedly the leading scientific society in the field of allergology. My dedication and commitment to EAACI goes back to 1992, since then I have participated in many different ways in the life of the Academy. The Barcelona congresses of 2008 and 2015 were large projects and I am proud to have collaborated so intensely on them. I know how EAACI works thanks to my participation for four years as a member at large on the Executive Committee (2013–17).

What are your objectives as Science Committee Chair?
My objectives are: to achieve added value for EAACI’s different scientific activities; to increase scientific knowledge of allergology amongst certain key groups, including university students, patients and their relatives; and to promote the development of precision medicine in allergology.

What are the challenges you foresee as Scientific Committee Chair?
A key challenge will be to increase the presence of allergology in university curricula. It is unacceptable that many young professionals do not know how to properly treat anaphylaxis, the main allergens (aeroallergens, food allergens, etc.) or the usefulness of specific immunotherapy as an etiologic treatment of allergic diseases. Additionally, today, in the 21st century, we have incredible opportunities to spread knowledge (websites, massive open online courses (MOOCs), digital books, etc.) that will allow us to improve the diagnostic approach taken towards allergic patients – and we need to take these opportunities. Finally, we cannot and should not want to forget our patients. We owe it to them, and with precision medicine (personalised, preventive, participatory and predictive) we will improve their quality of life. Recent diagnostic tools (such as molecular diagnosis) and therapeutic tools (such as monoclonal antibodies) have modified daily practice. Basic and clinical research remain fundamental in these years of progress in translational medicine.

**Edward Knol, Scientific Media Editor**

Tell us about yourself. What is your experience with EAACI?
I am a biomedical scientist and immunologist with a long-standing interest in allergy, currently working in the departments of immunology and dermatology/allergology in the University Medical Center in Utrecht, The Netherlands. Active in allergy research since 1985, my personal interest lies in translational research in allergy, including strong collaborations between basic scientists and clinicians. I became involved in the EAACI organisation when I joined the Local Organising Committee for the 2004 EAACI Congress in Amsterdam as scientific secretary. Since 2007 I have been more involved in EAACI activities after joining the board of the Immunology Section (2007–2013) and have been involved in several EAACI Task Forces. My last assignment with EAACI was as Scientific Programme Committee (SPC) Chair. In this position I took care of the scientific programme for the EAACI Congresses in Barcelona (2015) and Vienna (2016). Looking back at being the SPC chair, I feel honoured to have been part of such a fantastic organisational team.

What are your objectives as Scientific Media Editor?
In our community, scientific media are crucial in the spread of knowledge, whether by the more “classical” route via journals or via various social media. I consider the combination of both types to be of importance and would like to streamline the dissemination of the many accomplishments of EAACI’s initiatives, such as its meetings, courses, advocacy campaigns, guidelines initiatives, educational materials, using the wide variety of media channels available.

What are the challenges you foresee and what are your future plans?
The major challenge that I foresee is to keep a clear overview of all scientific activities within EAACI. However, I trust that the current team heading the diverse media, including EAACI HQ, will be of great help. In addition, I expect that the different EAACI initiatives will be actively contacting the relevant people to have their results posted in the proper media. In the short term, I plan to have more of the many EAACI Task Force initiatives in our media, since their activities are very important for our Academy and making them more visible will hopefully also promote new initiatives.
Dear colleagues, Dear friends

The 37th EAACI Annual Congress, to be held from 26 – 30 May 2018 in Munich, is now upon us. The good news is that poster submissions are breaking another record and that registrations are also very high.

Very exciting news this year is EAACI TV, which will broadcast activities live from the floor. We will convert the ‘Pro and Con’ area into a TV studio and broadcast the hottest Congress developments as well as several talks direct from Munich to around the world. EAACI TV will be available from our main webpage (www.eaaci.org) in a pop-up window during the Congress.

EAACI TV may contact you at the venue for an interview, giving you the chance to give your opinion; we hope whilst in Munich you will come and join us for this new experience.

EAACI TV will inform you in each morning about highlights of the day and we will also switch into the plenary sessions and invite speakers for interviews. Another intention is to make EAACI’s activities more visible: every year, a lot of volunteer work is undertaken in society and we want to give some of the groups responsible a platform to present their work and to acknowledge their contribution. EAACI TV also intends to attract other countries to join with us, and it is one of EAACI’s future visions to host satellite meetings in parallel with the annual meeting. If you realise that you have missed an interesting session, I recommend you to visit the Virtual Congress Hub, where you can watch session recordings even of posters, as part of the most comprehensive library we ever had at an EAACI meeting.

It is my very special privilege to welcome so many outstanding speakers to Munich and EAACI’s democratic Scientific Programme Committee, led by Susanne Halken and Mohammed Shamji, has organised an outstanding agenda. Have you thought about attending the Hot Topic session on the “Dieselgate affair”? This is a topic which very much affects Munich. We are excited to have a key expert on the stage, who is consulting for the government on this critical issue.

Our Junior Member poster session has always been a very intense area of discussion and these will be promoted even more this year by e-posters, allowing a better presentation of content. Interactive workshops will be offered on Sunday, Monday and Tuesday and a very new feature will be an interactive symposium on the management of insect venom allergies.

The atmosphere in the Exhibition Hall will be very energetic, with all available space being used by more than 50 exhibitors. Sponsors this year have been very active in gathering excellent and high quality sessions, some of which go beyond the limits of their actual sales portfolios and offer a lot of interesting talks as well.

If you are flying into Munich, you can take advantage of an EAACI shuttle bus which will operate on Saturday and Sunday from the airport to the ICM venue and on Tuesday and Wednesday from the venue to the airport, leaving every hour. Please note that there is also a highspeed train connection from Frankfurt airport to Munich central station (3h). You can buy a ticket for the public transport in the inner city with your registration.

We are also planning some additional surprises, even at the Opening Ceremony and Reception, including activities and items that we have not seen at previous meetings.

I look forward to seeing you in Munich.

Carsten Schmidt-Weber
EAACI Vice-President Congresses
EAACI Congress 2018 Chair
Lots of good reasons to attend the NAS Forum in Munich!

The National Allergy Societies Committee (NASC) is made up of representatives from each European NAS member of EAACI, with a chairperson and a secretary, and the chairperson of the International Societies Council (ISC). The NASC was founded in 2015 and the kick-off meeting was held in September 2015 in Zurich. Since then, several teleconferences and business meetings have been organised, as well as an annual NAS Forum at each EAACI Congress.

During the NASC Business Meeting in Munich (which will take place before the NAS Forum, by invitation only), an update will be made on Registries, old and new Working Group activities, and EAACI initiatives such as the idea of “dual membership” which was presented by EAACI President, Ioana Agache, at the last NASC meeting in January.

The purpose of the NAS Forum, open to everyone, is to present topics addressing local issues which may also be interesting for delegates from other countries. This year, we will have four speakers: three from European countries and one from the ISC. Standards of allergy care and allergy research are very different within the various EAACI members societies: Thomas Werfel, the current President of the German Society of Allergology and Clinical Immunology, will share details of progress made in his country; it will be equally interesting to listen to the second presentation on a similar subject from Aideen Byrne, from Ireland, where allergology does not even exist as a subspecialty.

For a perspective outside of Europe, the development of allergy care and allergology in Japan will be presented by Kenji Izuhara. Finally, Tari Haahletla will report on the Finnish Allergy programme (2008–2018) which is coming to an end but has already demonstrated that medical communities and the wider society can reduce disability and costs caused by allergy and asthma and improve public health.

Members of the EAACI leadership will also attend the Forum.

The NAS Forum represents an important opportunity to share different experiences and discuss possible solutions on different issues at national and International levels. We would also like to encourage you to visit the National Societies Village at the Annual Congress, which can be found in the first floor foyer at the International Congress Centre (ICM).

Visiting the Clinical Village during the EAACI Congress 2018

Once again, there will be a Clinical Village during this year’s EAACI Congress and it promises to be well worth a visit. Open on Saturday and Sunday (26-27 May), the Clinical Village offers an excellent opportunity for attendees to try out different procedures and equipment used in the diagnosis and treatment of allergic diseases. It provides a perfect platform to explore a combination of both theoretical and practical topics, both for specialists-in-training as well as for clinicians wanting to update themselves on topics adjacent to their core business. This year’s Clinical Village will have about 15 stands presented by experts in clinical procedures including: lung function and sports medicine, skin function testing (TEWL, corneometry), severe drug reactions, Mobile Health App, modern drug testing, anaphylaxis–emergency management, standardised patch testing, nasal and food challenges, photo allergy, exhaled NO measurement (FeNO), pediatric allergy school, pollen counts, in-vitro diagnosis (basophil activation test), ocular allergy and patient organisations. Admission is included in the registration fee and all registered attendees are invited to visit. The Clinical Village will be a particularly good complement to the EAACI postgraduate courses running on Saturday afternoon, combining theory with practice.

M. Beatrice Bilò
NASC Chairperson
Nanna Fyhrquist
NASC Secretary

Fourth EAACI NAS Forum
Tuesday, 29 May 2018,
15:30 – 17:00; Hall 13 b

Thomas Werfel, Germany:
The current situation of allergy care and allergy research in Germany.

Tari Haahletla, Finland:

Aideen Byrne, Ireland:
Organising allergy care in Ireland.

Kenji Izuhara, Japan:
The development of allergy care and allergology in Japan.

Visit the Clinical Village during the EAACI Congress 2018

Ulf Darsow
EAACI Local Organising Committee, Munich
Excitement is already building for the forthcoming EAACI Annual Congress in Munich, the ‘world city with heart’. The Congress looks very promising, especially for Junior Members who have a dedicated programme which is not to be missed!

The first JM activity in Munich will take place just after the Opening Ceremony, on Saturday, 26 May. The JM Poster Session will give juniors the chance to present their work in a friendly environment, chaired by both an EAACI junior and senior member. Prizes will be awarded after the session, during the Opening Reception.

The JM Symposium will be held on Sunday, 27 May. This year’s theme is ‘Cutting-edge developments in pediatric allergy’ and it will be a joint session bringing together representatives from the Junior Boards of different societies. Eric Schauburger (American Academy of Allergy, Asthma and Immunology) will give an insight into the role of atopic dermatitis and IgE sensitisation. Pavol Surda (European Rhinologic Society) will discuss the role of allergen immunotherapy in rhinitis during childhood. Sabine Barthel (European Respiratory Society) will talk about the relevance of the microbiome in pediatric asthma, while Alberto Alva-réz-Perea (EAACI JMA Board Secretary) will give an insight into the management of pediatric food allergy.

At the JM Educational Session, on Monday, 28 May, prominent seniors will present informative and inspiring talks sharing their own experiences: Ioana Agache, EAACI President, will talk about leadership and teamwork, while Roy Gerth van Wijk will discuss the situation of the allergy specialty in Europe. María José Torres will give an insight into national research networks as an opportunity for career progression, and Christian Apfelbacher will help us to understand the utility of reporting guidelines in clinical research.

Later on Monday, during the JM Business Meeting, juniors will have a chance to learn about the activities of the JM Assembly Board, but also will have the pleasure of listening to Peter Hellings, EAACI Secretary General, who will give a talk on how to build an international professional network.

Last but not least, on Tuesday morning, 29 May, the Case Reports Session will feature ten juniors who will present different clinical cases; the three best will be awarded generous prizes. On that evening, juniors will head off to the JM event in a unique location in Munich. It will be a fantastic way to close the JM programme of the EAACI Annual Congress. We look forward to meeting you all in Munich!

Alberto Alvarez-Perea
JMA Board Secretary

Presidential Symposium in Munich: Uncovering the environment–immune connection

The PRACTALL program is a joint initiative of EAACI and the American Academy of Allergy, Asthma and Immunology. It focuses on practical aspects of allergy to deliver updated and evidence-based recommendations for clinicians.

The upcoming PRACTALL is an initiative of the EAACI President and focuses on the role of exposomics as a novel approach to tackle allergic diseases and asthma.

The Presidential Symposium in Munich will highlight the key points of the consensus document from novel mechanisms of immune tolerance and early life events shaping the immune system to the role of exposure biomarkers and the integration of exposomics with the metabolome, transcriptome and epigenome.

Join us on Monday, May 28, at 10.45 – 12.15 for a lively debate on hot topics such as population level vs a personalised medicine approach, the mechanisms of environmental endotypes, populations of interest, complex unifying models based on language standards for exposures, and many more.

Ioana Agache
EAACI President
THE NEEDS OF ALLERGIC PATIENTS AND HOW TO ADDRESS THEM

MUNICH

SUNDAY 27 MAY 17:30 – 19:00 / HALL 5

Chair’s welcome and introduction
Marcus Maurer, Germany

Matching the ARIA guidelines to new technologies
Jean Bousquet, France

Rupatadine in allergic rhinitis: a treatment for all patient types
Susan Waserman, Canada

Rupatadine in dermatology, beyond urticaria
Masatoshi Abe, Japan
Looking forward to the EAACI Annual Congress #EAACI2018, in Munich, we would like to underline several important scientific benefits of attending. In Munich, you will be challenged by high quality learning opportunities, discovering new developments in our research areas and exchanging ideas. In addition, you will be able to take advantage of numerous networking opportunities with leading allergists and clinical immunologists from around the globe at the world’s largest and most influential allergy, asthma and clinical immunology meeting!

During the EAACI Annual Congress, dissemination of knowledge will be accelerated by inventive and innovative techniques. Modern means to access scientific information will include digital accessing/streaming of information/content on smartphones, computers and large-screen systems, including via the EAACI App and EAACI TV. Social media activists in the allergy and clinical immunology world will be able to directly interact at the Tweetup cocktail and in friendly meeting areas. Although it is almost impossible to entirely regulate wider engagement and discussions on social media, it is recommended that social media users respect the meeting’s professional etiquette and rules. Responsible posting is encouraged, avoiding non-professional posts or inaccurate content. It is important to differentiate your personal comments/viewpoints from those of speakers/presenters, and it is highly recommended that EAACI’s clear filming, photography and recording policy for EAACI events be respected (see: www.eaaci.org/eaaci-congresses/eaaci-2018/eaaci-media-and-embargo-policy), especially with regard to copyright and intellectual property infringement. Try to avoid misquoted or confusing information, and avoid misinformation possibly generated by the brevity of some social media posts.

That said, please do use social media to share news of presentations and discussions at our meeting as much as possible. In order to enhance the #EAACI2018 meeting experience, the active and responsible involvement of social media users is needed. Event-related content posts should include the meeting hashtag #EAACI2018. Sharing information about the event, its venue, programme and social activities is also useful for the Congress’s online visibility. Keeping meeting discussions flowing, engaging influencers and responsible social media activists in order to add value to online interactions and to encourage participation are key goals for the positive involvement of social media at our meeting.

We appreciate that social media will help tremendously to spread the many novel developments to be presented during the EAACI Annual Congress and we hope that the advice above will help us all to streamline this flow of knowledge.

Florin-Dan Popescu
EAACI Social Media Editor

Edward Knol
EAACI Scientific Media Editor
EAACI HQ Corner

The congress countdown is on!

As we enter May, the month of the EAACI Congress 2018, the EAACI Headquarters office is buzzing with final preparations. Given that the set-up for each congress, by far our largest annual project, takes around 36 months from start to finish, the last weeks before a congress is a rather exciting period – with a whole lot to do!

Membership

It makes sense to be a full EAACI member when attending congress as you benefit from paying up to 30% less for registration. As the congress approaches, we are busy processing new membership requests and answering member questions. Typically, over half of all congress participants are non-EAACI members, so during the congress we always have a counter where people can join and learn about all included benefits. This year the counter is near the West Entrance: we encourage you to bring any colleagues who may want to join.

Congress & Events Team

The HQ Congress & Events Team are at the heart of planning all EAACI events. From finding a location, setting-up contracts and leading coordination of all congress partnering companies, it starts here, so standing in the middle of the largest allergy and clinical immunology congress in the world, this is the best infrastructure set up is rather impressive. We look forward to welcoming even more participants in light of this.

The project management of announcing and administering the 300 EAACI Scholarships and Poster Prize winners is also steered from headquarters. Additionally, the education team in Zurich manages the CME application process. This year we are proud to have increase the number of CME credits to 30, in comparison to 24 in previous years.

Executive Team

As our largest event, the congress is the perfect place to check the status of all projects and exchange ideas on future plans. A great number of management meetings take place during congress week with the focus on continuously driving EAACI’s strategy. Much time is taken throughout the year in coordinating EAACI Sections, Interest Groups, Working Groups and Task Forces. The congress presents a wonderful opportunity for us to catch up with all colleagues in person.

Marketing & Communication

Promotion of each congress starts during the preceding one. By this point in the year, we have been informing everyone about all the exciting activities to look forward to at Munich for 12 months whilst, in parallel, preparing communication material for the EAACI Congress 2019 in Lisbon.

The congress has so much going on, and it is our job to help you plan well and not miss sessions of interest. To do this, we have created the EAACI App as a useful tool to organise your visit. We are particularly excited about the launch of a new and improved EAACI Media Library in which you can view hundreds of webcasts taken from the congress.

Public Relations & Publications

Being the largest allergy and clinical immunology congress in the world, this is the best platform to present new findings and celebrate pioneering successes in the field. With so much to report, we welcome medical journalists to spread the latest news, each year coordinating the attendance of over 50 journalists from around the world to do just that.

Congress is also an important meeting for people to learn more about EAACI’s three leading journals and their latest developments. This year each journal has a stand situated close to the EAACI Counter in the main hall.

We look forward to seeing you in Munich!

Warm regards,

Your EAACI HQ Team

About EAACI Headquarters

As EAACI has grown over the years, so has the need for it to become more structured, to manage the increasing range of our activities. In 2009, the EAACI headquarters opened in Switzerland, with the objective of working in unison with all members of the EAACI family, and to continuously professionalise and further develop our activities. Currently we are a small and motivated team of 11 based in Zurich.

Our Congress Highlight

Getting some fresh air at the allergy run on Monday evening.

Saying hello and answering your questions at the EAACI Counter

Witnessing the before and after of the infrastructure set up is rather impressive
German Society for Allergology and Clinical Immunology

The German Society for Allergology and Clinical Immunology (DGAKI) is a non-profit-making registered scientific society which has grown to be the leading platform for research and education in the field of allergology in Germany. The society was founded in 1951 and now has about 1450 members.

The DGAKI has seven sections and currently has six task forces. It organises conferences and workshops, as well as awarding prizes for outstanding research and publishing Allergo Journal, a renowned research-oriented journal in the field of allergology which is now supplemented by Allergo Journal International which is read in about 99 countries and listed in PubMedcentral.

As a scientific society, DGAKI is responsible for the development and regular updating of guidelines regarding diagnosis and treatment of allergies, in coordination with the German national authorities (AWMF) and in cooperation with other professional organisations.

One of the Society’s main tasks is the support of young scientists, creating a platform for the exchange of ideas and experience at a national and international level. Its aim is to stimulate and support research about allergy-related topics and convey deep understanding to practitioners and researchers alike for the benefit of patients.

DGAKI has established regular training courses for young scientists and physicians based on an allergology curriculum and offers a wide range of focused workshops giving comprehensive updates on different aspects of allergy under the roof of Allergieakademie. For further information: www.allergieakademie.de or mail info@dgaki.de.

As a common initiative of the German Society for Allergology and Clinical Immunology, the German Society of Dermatology and the German Respiratory Society, a new certified step-by-step concept to guarantee high quality medical staff to deal with the increasing quantity of allergy patients was established in 2014: Comprehensive Allergy Centres (CAC) are certified according to a specifically developed certification process based on the quality management claims of modern medicine. Since 2014, six CACs have been certified and recertified in Germany.

For further information on CAC and on our guidelines, upcoming workshops and the attractive conditions offered for Junior Members, please meet us at stand C.08 in the Clinical Village at the EAACI Annual Congress in Munich, or visit our website: http://www.dgaki.de.

DGAKI Executive Committee:
Thomas Werfel, President
Eckard Hamelmann, Vicepresident
Harald Renz, Past President
Christian Taube, Secretary General
Margitta Worm, Treasurer

A few words from the Website Editor

The EAACI website is constantly being improved and updated. It is a group effort by people who are keen to develop the best tools for members and to provide fresh news all the time. Indeed, the website is regularly updated with the very latest event and meeting information.

Don’t forget that you can also find all the details you need on the website for the EAACI Annual Congress taking place in May, as well as other past and future events. I wish all Congress participants a very fruitful and interesting meeting. The Congress is a good opportunity to meet and to get your voice heard. A number of meetings to discuss website issues will take place: the Editors Meeting, followed by the Communication Council Meeting (Saturday, 26 May); and the Web Committee Business Meeting (Tuesday, 29 May). Invitations have already been sent and I count on your attendance. Anyone who wants to meet me in person during Congress is more than welcome to do so: please email me at webeditor@eaaci.org to make an appointment.

If you missed a presentation at one of our meetings, including at the Annual Congress itself, or even if you attended a meeting but would like to see it again, why not try our webcast area? Selected presentations can be found there and you can watch them at home at your convenience. You can access the website from your mobile phone, tablet or computer; why not give the site a try while you are waiting for your flight or travelling by train?

I encourage you to visit the EAACI Job Center. You can reach it by clicking the tab in the upper right-hand corner which appears on all pages on the website. There, you can find informations about job offers from all around the world. If you would like to submit a job application, please use the online form. All vacancies are subject to a review process before being published in the Job Center and offers from industry will be rejected.

Don’t miss a great opportunity to stay up-to-date with our evolving specialty and visit our website any time! And please don’t hesitate to contact us with any comments or suggestions.

Have a great summer!

Sylwia Smolinska
EAACI Website Editor

www.eaaci.org
PAI: in search of scientific excellence

Pediatric Allergy and Immunology (PAI) is the world’s leading journal in its field, achieving an impact factor of 3.775 in 2016. The aim of the journal is to publish clinical and research articles related to clinical and experimental pediatric allergy and asthma, as well as in clinical immunology related to children. Each year, we publish around 100 articles across 10 issues. The peer review selection process is rigorous and only the best 25% of the 400 submissions received each year are published. Besides original articles, PAI also has a ‘Letters to the Editor’ section allowing us to publish clinical cases or short scientific reports.

The new editorial team is devoted to nurturing the scientific excellence of the journal and to developing its position in the world of pediatric allergy and immunology. PAI is truly an international journal and besides its strong anchorage in Europe as the official EAACI journal, it also has strong links to scientific societies in Asia, the Pacific area, as well as in the Americas and in Africa. We are strongly committed to this international dimension which we aim to develop.

PAI also aims to be a link between the academic world and practicing allergists. Besides original scientific publications, we would like to provide practicing allergists with in-depth reviews on various topics as well as with stimulating opinion articles on disputed areas. Our ‘Letters to the Editor’ section should also allow a better interaction between authors and readers of the journal.

The scientific publishing world is a rapidly changing one and PAI is strongly committed to meeting these changes with innovative solutions. The journal is lucky enough to have committed authors and readers and, in the coming years, PAI will continue to evolve and meet the expectations of all our stakeholders, with the main aim of building on its scientific excellence.

Philippe Eigenmann
Editor-in-Chief
Pediatric Allergy and Immunology

CTA: onwards and upwards

Clinical and Translational Allergy (CTA) is a journal aimed primarily at clinicians practising across the diverse fields of allergy. It offers the latest in clinical and translational research, reviews and position papers. CTA is also a useful repository for abstracts presented at EAACI focused meetings. Presented in an on-line format, it is free to view and download for its international readership. It has attracted an increasing number of high quality international submissions since its launch Impact Factor of 3.239 in 2017 and we hope that the impact factor for 2018 will be going up. The enthusiastic engagement of EAACI Junior Members has helped to provide a platform for all those with an interest in allergy, including young and experienced researchers, health care providers, purchasers, politicians and the public.

Although on-line publishing allows the inclusion of unlimited material without additional costs (including videos and other detailed supplementary material where relevant to the paper), the editors are committed to promoting brevity and clarity of articles to ensure that the message remains focused, easy to read and easy to understand. We encourage the submission of original research articles in all areas of allergy relevant to patient care, letters outlining latest research findings, reviews covering hot topics and position papers from working groups and task forces as a vehicle for promoting and disseminating the ongoing work of the Academy.

Our refreshed Editorial Board members are committed to the fast and fair peer review of submitted manuscripts. CTA is your journal. Thank you for supporting it.

Clive Grattan and Jean Bousquet
Joint Editors-in-Chief
Clinical and Translational Allergy
Congratulations to 2018's fellowship winners

The EAACI fellowships exist to foster the exchange of knowledge and techniques amongst European laboratories and hospitals. We wish all the fellowship winners an interesting and enriching placement abroad.

**RESEARCH FELLOWSHIPS**

**SHORT TERM** (3 months)

- Katrine Tange
  - Callesen, Denmark
  - Serbia
- Ibon Eguiluz-Gracia
  - Spain
- Marta De Los Reyes Jimenez
  - Germany
- Margherita Deidda
  - Italy
- Tatsiana Vladimirovna Hlinkina
  - Lithuania
- Majda Dzidic
  - Spain
- Inês Ribeiro Paciência
  - Portugal

**MEDIUM TERM** (6 months)

- Juan Rodriguez-Coira
  - Spain
- Galber Rodrigues Araujo
  - Brazil
- Filipa Matos Semedo
  - Portugal
- Marija Branimir Perusko
  - Serbia
- Charlotte Moulin
  - Belgium

**LONG TERM** (12 months)

- Naiera Medhat Zayed
  - Egypt
- Marsela Dervishaj
  - Albania
- Justyna Czeladzka
  - Poland

**CLINICAL FELLOWSHIPS**

(3 months)

- Marija S. Stankovic
  - Serbia
- Indrashis Podder
  - India
- Bárbara Alexandra De Kong Cardoso
  - Portugal
- Murat Türk
  - Turkey
- Maria Dolores Guerra Vilaplana
  - Spain

- Manar Farouk
  - Mohamed Ali
  - Egypt
- Ilaria Lazzarato
  - Italy
- Karthik Nagaraju
  - India
- Gintare Paulikaite
  - Lithuania
- Noura Mohammad Shakaroun
  - Lebanon
EAACI Task Force on public outreach activities on immunological mechanisms in allergies and asthma

Allergy affects approximately 150 million European citizens, yet knowledge about the relevant mechanisms in general society is still limited. Therefore, the Board of the EAACI Basic and Clinical Immunology Section decided to make it one of its aims for the years 2017–2019 to highlight the available knowledge on complex immunological mechanisms in an easily understandable way.

At every congress and meeting and in countless manuscripts, EAACI experts communicate novel findings associated with the onset and progression of allergic diseases. However, clinicians and researchers should disseminate this knowledge not only to other experts, but also translate it into easily understandable language for the general public, politicians, administrators and potential donors. Adequate education of patients and their families plays an important role in everyday clinical work to ensure the full success of medical treatment. Therefore, at the beginning of this year, we initiated a Task Force dedicated to translating emerging knowledge regarding immune mechanisms underlying allergic diseases and asthma for the broader public.

We aim at a long-lasting awareness campaign with the use of various open-access educational resources. The target audiences for this initiative are the general lay public and patients, as well as students, early researchers, clinicians and other health care professionals not specifically trained in immunology. Every year, among other things, an animated cartoon video will be produced and advertised. This year’s video will cover immune mechanisms of food allergy and current concepts for its prevention.

All EAACI opinion leaders and EAACI members working on this topic are warmly welcome to contribute to make this Task Force successful. Help us to make scientific and clinical knowledge available for everyone! We will need your feedback regarding topics of interest for animated cartoon videos and your help in translation of public outreach materials into a range of European languages. We are very grateful for the support being given by EAACI’s education and communication teams and especially by the EAACI Board of Officers. In addition, a close collaboration with EAACI Junior Members has been established and highly talented junior members are already contributing to our outreach activities, such as blog initiatives highlighting the scientific interests of the authors.

Eva Untersmayr-Elsenhuber
Task Force Chair

Milena Sokolowska
Task Force Secretary

Jürgen Schwarze
Immunology Section Chair

Florentina Sava
Immunology Section JM Representative

EAACI guidelines on the use of biologics in allergic diseases and asthma

Delivering high-quality clinical care is a central priority for allergists and related specialists caring for patients with allergic diseases and asthma. EAACI is continually developing and updating resources to help healthcare professionals and researchers to design the best interventions, deliver high standard care and to assess their actions and decisions for purposes of quality improvement and/or reporting. Guidelines are developed using a systematic process, and are based on available evidence and the clinical experience and expertise of all interested stakeholders.

EAACI developed a position paper on biologics in 2015. Due to the rapid accrual of evidence and new therapies, advancement of guideline development methodologies and the need to broaden the scope of the 2015 recommendations, new guidelines are therefore needed.

The EAACI guidelines for the use of biologics in allergic diseases and asthma will address several major topics, from a revised nomenclature to factors influencing efficacy/achieving a disease-modifying effect and safety, and to the use of biologics in pregnancy and in pediatric, elderly patient and high-risk populations.

The Core Leadership met with the Content Panel on 5 April 2018 in Zurich and agreed on the general methodology and timelines. The whole EAACI community will be involved in this initiative from the very beginning (providing input for the PICO questions) to the very end (by commenting on the final recommendations).

Ioana Agache
Marek Jutel
Oscar Palomares

EAACI Biologics Guidelines TF Chairs
2018 #EAACI Allergy Schools in Tweets

Tweets and the use of other social media can really help to get the message out about EAACI events to a much wider audience. This page shows a selection of tweets sent at two recent, successful EAACI schools

Basic Immunology Research in Allergy and Clinical Immunology Winter School
25–28 January 2018, Saas-Fee (Switzerland)
#EAACI Winter School #EAACIWS18

EAACI Allergy School on Aerobiology and Pollution
15–17 March 2018, Dubrovnik (Croatia)
#EAACI Allergy School #EAACIAS18
The second EAACI Practical Allergy Diagnosis (e-PAD) event arranged by the EAACI Interest Group on Allergy Diagnosis and Systems Medicine (IGADSM) was a master class held in March this year in the historic Schloss Rauischholzhausen near Marburg in Germany (where the Marburg virus was discovered).

The master class was attended by 35 delegates: most from European countries (many from Germany, Belgium, Sweden and Switzerland) and one each from Japan and Sri Lanka. These advanced allergists received a brush-up in diagnostic approaches with alternating plenary lectures and small group symposia in which they got close to the specialists and could ask questions and resolve uncertainties. We had a festive dinner at the superb Bückingsgarten in Marburg, where new friendships were found and old ones confirmed.

The programme focused on cutting edge diagnostic methods: molecular and cellular allergy diagnosis; mobile health technology; and diagnostic approaches to major allergic conditions in secondary care by seasoned allergists.

The master class was opened by Professor Harald Renz, of Marburg University, who discussed the scope of future in vitro diagnostic approaches. The first session gave an overview of allergy at a molecular and cellular level. The second and third sessions dealt with molecular and cellular diagnostics, and in the fourth session current approaches to major allergic conditions (food allergy, allergic airway diseases and insect venom allergy) were covered. In between, delegates rotated through three small group symposia covering molecular and cellular diagnostic approaches and mobile health apps. There was time for questions and discussions.

The e-PAD approach of integrating all diagnostic tools in one meeting is useful to sharpen the diagnostic ability of participants, and to update seasoned allergists with new diagnostic opportunities in a secure and stimulating environment. It also gives senior staff the opportunity to become better acquainted with techniques that were developed after they trained.

In discussion during the ensuing IGADSM board teleconference, e-PAD was considered to be a success. We would like to include more organ-specific allergen provocation in a future e-PAD.

Hans Jürgen Hoffmann
IGADSM Past Chair

Chrysanthi Skevaki
Local Chair

Paolo Matricardi
IGADSM Chair

---

EAACI e-PAD Master Class highlights

---

EAACI Newsletter

#51 • Volume 2 • 2018

---

Agenda

---

FAAM 2018
18 - 20 October 2018
Copenhagen, Denmark

5th Food Allergy and Anaphylaxis Meeting

www.eaaci.org/faam2018
One of the main factors influencing our quality of life is our environment. Some people want everything green, some people want modern shopping malls. None of these things are of any use if your health is bad. We understand this: we exercise more, we eat healthier, we do yoga. Obviously we can further increase well-being, or else there would be no need for a workshop on environmental factors in allergies. Of the many environmental threats we face, such as plastics, noise and water pollution, air pollution is ubiquitous and influences our quality of life – or at least our perception of it.

Although cardiovascular diseases and cancer still remain responsible for most deaths in Western countries, one of the problems in modern society is the constant increase in immunologic diseases. You don’t die from psoriasis, and don’t die immediately from diabetes or let alone from allergies (except anaphylaxis). However, allergies are important in the lives of many modern citizens.

Having a healthy life greatly improves your quality of life. To make our lives better everybody can contribute, particularly those of us in the medical profession, and the EAACI Allergy School, held in March this year in Dubrovnik, Croatia, aimed to investigate some of the problems we face and our responses to them.

In many western countries the number of individuals with an allergic sensitisation is steadily rising. Currently in Europe, the rate is about 40–50%, with younger generations having higher rates than the older ones, so that by 2040 we are expected to reach a peak in allergic sensitisations. Worse, it is not abating. In Singapore, about 80% of the younger population has an allergic sensitisation. Thus, the allergic epidemic is by no means over and there is no plateau in sight.

What can we do? We need to become aware that the environment is important for allergic diseases. We need to get to know the facts. And we need to talk about it to everybody we can, especially governmental health officials.

We are living in a high-tech society with high-tech problems. Making an analogy with airplanes: if we ignore the many small warning lights in the cockpit and just remove red warning lights from the alarms, if we pull out sufficient control lights (like removing certain bacteria from the diet or accepting air pollution or climate change), sooner or later the plane will crash. In the case of an allergic crash, we could be living in a paradise but no one would enjoy it: sneezing, red eyes, no breath due to asthma, bad stomachs, diarrhoea, itchy skin, psoriasis, etc.

At the EAACI Summer School in Dubrovnik, Croatia, we tried to understand the many red lights and how to repair the problems instead of just ignoring them and hoping they go away, keeping in mind that the causes of allergic diseases due to Western life styles are still not understood, and there is a lot to learn. Doing nothing is not an option, unless you don’t mind an allergic crash.

The school was held in a wonderful location, with good lecture equipment, a nicely ventilated lecture room, and great catering and accommodation. About 80 participants joined in the sessions and the workshops. We covered the history of the allergy epidemic, the current allergic epidemic, the microbiome, air pollution, the effects of helminths, pollen, moulds and other environmental factors influencing allergic diseases. We had ample time for discussion, including in the workshops where we worked in small groups, even working in pairs with 10 on-site microscopes for pollen and mould analysis, computer programming or microbiome analysis.

We had a wonderful dinner and city walk in the historic city of Dubrovnik with views of the harbour and fortress: Game of Thrones in real life!

The school was a joint effort of the WG on Aerobiology and Pollution and the WG on Infection and Allergies. We would like to thank Enna Heller, Jeanette Kobler and Aikaterina Klimogianni for their excellent help in organising the event, and EAACI for financial support. Judging from the positive reactions from the participants and lecturers from all over the world (including from Australia, South Africa and Korea) this will not be the last school on environmental factors in allergic diseases!

Jeroen Buters
EAACI WG on Aerobiology and Pollution
Hermelijn Smits and Tuomas Jarntti
EAACI WG on Infections
The EAACI Asthma, ENT and Immunology Sections joined forces for a Master Class on Biologicals (held in April 2018 in Prague, The Czech Republic), integrating novel insights into immunologic mechanisms, including interactions with microbiome with innovative approaches to phenotypes, endotypes and clinical applications of biomarkers for targeted therapies with biologicals and small molecules in asthma and comorbidities.

The translational nature of the Master Class was reflected by integrating basic science into clinical practice. Therefore, the programme also included a clinical workshop and patient case presentations both from experts and participants. To ensure optimal interaction between the 14 faculty members (including EAACI key staff and several global experts) and the participants, only a limited number of registrations were granted.

At a higher level, the Master Class also represented a kick-off for the Presidential project on Guidelines for Biologicals. Ioana Agache stressed the need for phenotyping and endotyping for adequate asthma management and the need for validated biomarkers.

The proceedings of the Master Class will be published in the EAACI journal *Allergy*.

---

Zuzana Diamant  
Local Organising Chair and EAACI Asthma Section Chair  

Ioana Agache  
EAACI President  

---

The Master Class on Biologicals in Prague was of great value with outstanding national and international speakers. The data presented included state-of-the-art knowledge, treatment recommendations, interpretation and guidance through both daily and rare topics. Also, non-published data were presented giving an update on the current cutting edge of developments. The social programme and venue location were well-selected. Lots of occasions during the programme gave the possibility for individual exchanges. In total it was a very concise, highly informative, perfectly organised and valuable Master Class which I can definitely recommend. Many thanks to the organisers and speakers.

Antonios Kolios  
EAACI Junior Member and Master Class Participant
Mast cell disorders: Helsinki Congress 2017 report

Sigurd Broesby-Olsen (Denmark), Torsten Zuberbier (Germany), Marcus Maurer (Germany) and Cem Akin (USA) all made interesting and useful contributions concerning mast cell disorders during last year’s EAACI Annual Congress in Helsinki.

Mast cells play a key role in the repairing of damaged tissues. Degranulation is required to provide a protective response against excessive environmental factors, as well as parasitic invasion.

Mast Cell Disorders represent a broad group of conditions associated with mast cell activation that can be localised or systemic. They are classified as:

- primary (clonal): systemic mastocytosis and monoclonal mast cell activation syndrome (MMAS);
- secondary (non-clonal): allergic conditions, chronic inflammatory and neoplastic disorders, inducible urticaria; and
- spontaneous (idiopathic): anaphylaxis, urticaria, angioedema.

Disorders of mast cells are linked to symptoms that involve many organs, from cutaneous manifestations to gastro-intestinal, neurological, cardio-vascular and idio-pathic (spontaneous) anaphylaxis.

The mechanism is driven by the effects (on receptors on blood vessels and nerves) of histamine, tryptase platelet activating factors, as well as other bio-active substances including cytokines and chemokines that are released during degranulation.

In addition to serum mast cell tryptase, the measurement of urinary mast cell activation biomarkers can aid in the initial evaluation of suspected cases of mast cell disease. The urinary histamine metabolites methylhistamine (MH) and methylimidazole acetic acid (MIMA) in 24-hour urine or in a urine sample in the fasting state, and 11-beta prostaglandin F(2) alpha [a metabolite of prostaglandin D2 (23BPG / 2,3 Dinor-11Beta-Prostaglandin F2 Alpha)], Leukotriene E4 (LTE4) [a biomarker of total cysteinyl leukotriene (cys-LT) production] are all associated with accelerated mast cell activation.

An increase in the number of mast cells is linked with genetic mutations: in adults the leading mutation is D816V mutated KIT which is considered to play a role in changes of proliferation and apoptosis, but in the paediatric population other mutations have been linked with this condition. Genetic testing is at the centre of the diagnostic process, alongside detection of mast cell tryptase and clinical assessment.

Management of mastocytosis should be multidisciplinary and is comprised of emergency medication for adults (spontaneous anaphylaxis), a high dose of type one antihistamines, followed by inclusion of type two antihistamines, leukotriene receptor antagonists and Anti IgE.

In urticaria and angioedema symptoms occur due to spontaneous or inducible degranulation of mast cells. Mechanisms of mast cell activation include auto-immunity: anti FcεR antibodies of IgG type, anti IgE antibodies of IgG type, and auto-antigens.

A recent review of Global Guidelines has streamlined the treatment strategy for primary and secondary care settings.

Michael Rudenko
Consultant Allergist and Clinical Immunologist
London Allergy and Immunology Centre

For more information visit www.eaaci.org
UPCOMING EAACI EVENTS

Annual Congress 2019

EAACI Congress 2019
1 – 5 June 2019
Lisbon, Portugal
www.eaaci.org

Focused Meetings

Food Allergy and Anaphylaxis Meeting (FAAM 2018)
18 – 20 October 2018
Copenhagen, Denmark
www.eaaci.org/faam2018

European Consortium on Application of Flow Cytometry in Allergy (EUROBAT 2018)
18 October 2018
Copenhagen, Denmark
www.eaaci.org/eurobat2018

International Severe Asthma Forum (ISAF 2018)
8 – 10 November 2018
Madrid, Spain
www.eaaci.org/isaf2018

Skin Allergy Meeting Joint meeting with ESCD (SAM 2019)
4 – 6 April 2019
Munich, Germany
www.eaaci.org/sam2019

Allergy Schools

www.eaaci.org/allergy-schools

Allergy School on Immunotherapy in children for the treatment of respiratory and food allergy
20 – 22 September 2018
Barcelona, Spain

17th EAACI Immunology Winter School “Basic Immunology Research in Allergy and Clinical Immunology”
24 – 27 January 2019
Trysil, Norway

For more information visit www.eaaci.org or contact events@eaaci.org